| Description |
1 online resource (x, 455 pages) : illustrations (some color) |
| Series |
Handbook of experimental pharmacology, 1865-0325 ; v. 213 |
|
Handbook of experimental pharmacology ; v. 213. 0171-2004
|
| Contents |
Clinical instruments to evaluate and guide treatment in schizophrenia / Stephen R. Marder -- Cognitive impairment in schizophrenia / Richard S.E. Keefe and Philip D. Harvey -- Behavioral animal models to assess pro-cognitive treatments for schizophrenia / Jared W. Young, Nurith Amitai and Mark A. Geyer -- Towards medication-enhancement of cognitive interventions in schizophrenia / Hsun-Hua Chou, Elizabeth Twamley and Neal R. Swerdlow -- Mutant mouse models in evaluating novel approaches to antipsychotic treatment / Colm M.P. O'Tuathaigh, Lieve Desbonnet and John L. Waddington -- 5-HT2C agonists as therapeutics for the treatment of schizophrenia / Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross and John Dunlop -- The role of dopamine D3 receptors in antipsychotic activity and cognitive functions / Gerhard Gross and Karla Drescher -- Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the [alpha]7 nicotinic receptor / Ann Olincy and Robert Freedman -- Muscarinic mechanisms in psychotic disorders / David L. McKinzie and Frank P. Bymaster -- Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications / Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu and Glenn Konopaske -- Metabotropic glutamate receptors for new treatments in schizophrenia / E.J. Herman, M. Bubser, P.J. Conn and C.K. Jones -- Glycine transport inhibitors in the treatment of schizophrenia / Daniel C. Javitt -- Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia / Francine M. Benes -- Development of disease-Modifying treatment of schizophrenia / Anton Bespalov, Corinna Klein, Berthold Behl, Gerhard Gross and Hans Schoemaker |
| Summary |
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications |
| Analysis |
Medicine |
|
Toxicology |
|
Pharmacy |
|
Psychopharmacology |
|
Applied psychology |
|
Biomedicine |
|
Pharmacology/Toxicology |
|
Biological Psychology |
| Related To |
Companion volume: Current antipsychotics. Heidelberg ; New York : Springer, ©2012 9783642257612 |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record and online resource; title from PDF title page (SpringerLink, viewed September 24, 2013) |
| Subject |
Schizophrenia -- Treatment
|
|
Schizophrenia -- Chemotherapy.
|
|
Pharmacology.
|
|
Antipsychotic Agents -- pharmacology
|
|
Schizophrenia -- drug therapy
|
|
Pharmacology
|
|
pharmacology.
|
|
PSYCHOLOGY -- Psychopathology -- Schizophrenia.
|
|
Pharmacology
|
|
Schizophrenia -- Chemotherapy
|
|
Schizophrenia -- Treatment
|
| Form |
Electronic book
|
| Author |
Geyer, Mark A., editor
|
|
Gross, Gerhard, active 2012, editor.
|
| ISBN |
9783642257582 |
|
3642257585 |
|
